Sponsor or institution
Clinical trials and research at Scripps Research Institute, the
As of November 12, 2026, Find a Trial lists 410 NIH-funded research projects at this institution, with $411.3 million in listed awards. Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 410NIH research projects
NIH-funded research (newest 40 of 410)
Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
-
Targeting key coronavirus proteins with new compounds
Researchers are developing new chemical compounds to block important coronavirus proteins, aiming to stop replication across multiple strains for patients who have or may face COVID-19.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
Animal and organoid models to test new antiviral drugs for COVID-19 and related viruses
A national research grant supports scientists at Scripps to develop and use animal and organoid models to screen and study new antiviral medicines for COVID-19 and similar viruses.
-
ADME/Formulation Core supports drug development
A research team is building a core unit to study how potential drugs are absorbed, distributed, metabolized, and eliminated, and to develop stable formulations to support testing in humans.
-
Medicinal chemistry hub for antiviral drug discovery
A dedicated medicinal chemistry core at Scripps Research helps drive early drug candidates for antiviral treatments with partners, from hit optimization to preclinical planning.
-
HTS Core supports fast antiviral drug discovery for COVID-19
A center-wide effort to quickly screen huge collections of small molecules to find potential COVID-19 medicines.
-
Administrative Core for a multi-institution antiviral drug research center
This grant funds an Administrative Core to coordinate a large, multi-institution antiviral drug research center focused on AIDS and related viruses, helping researchers work together efficiently.
-
Antiviral Medicines Center for Pandemic Readiness
A large NIH program aims to speed up discovery of oral antiviral drugs and other treatments to protect people from current and future deadly viruses like coronaviruses, flaviviruses, and hemorrhagic fever viruses.
-
eDyNAmiC: Understanding extrachromosomal DNA in cancer
A study at Scripps aims to understand how circular ecDNA in cancer drives aggressive tumors and how we might target it to help patients.
-
Center for Viral Systems Biology: Outbreak.info for real-time outbreak intelligence
A researchers’ team is building real-time, virus-tracking tools to help detect and interpret outbreaks like bird flu faster, using open data and new analysis methods.
-
Reversing Immune Dysfunction for HIV-1 Eradication
A team is testing how to restore the immune system in people with HIV to help clear the virus from the body.
-
Glycoengineering HIV-1 Env vaccines to boost immune response
Researchers are testing a new way to make HIV vaccines more immunogenic by altering sugar molecules on the virus envelope to provoke stronger protective antibodies.
-
Finding medicines that boost cells' stress-protection to help preserve brain cells
Researchers are developing small molecules that turn on a cell's natural stress-response to try to protect people with Alzheimer's and related dementias.
-
Reprogramming B cells to make powerful HIV antibodies
This approach tries to reprogram people's B cells so they continuously make potent antibodies that block HIV.
-
Center for Rational HCV Vaccine Design and Evaluation
This NIH grant supports a major effort to design and test vaccines against hepatitis C by guiding the immune system to target conserved parts of the virus.
-
Chemical inducers of proximity to block FOXA1 in breast cancer
A cutting-edge drug-like molecule is being explored to block a key cancer gene, FOXA1, which helps breast cancer cells grow and spread.
-
Understanding how MPXV antibodies block mpox infection in humans
Aims to map how antibodies from people exposed to mpox or mpox vaccines recognize and block monkeypox virus to guide better treatments and vaccines.
-
Oral insulin-inspired discovery using expansive DNA-encoded libraries
This grant aims to find new oral drug candidates that activate the insulin receptor, potentially reducing injections for people with diabetes.
-
Dendritic cell targets to boost T cell vaccines for HIV and other infections
A study exploring how different dendritic cells can be targeted to better activate T cells and improve vaccines against HIV and other intracellular infections.
-
Understanding how long-lived plasma cells work and survive beyond making antibodies
Researchers are studying what makes certain plasma cells live for years and how they decide their fate, with findings that could improve vaccines and immune protection.
-
How long plasma cells live after mucosal infections
Researchers are studying why some antibody-producing cells at mucosal surfaces stick around for years to protect against infections like flu.
-
Understanding how membrane proteins fold and work using simple designed building blocks
Researchers are testing new, simple-designed membrane proteins to learn the rules that govern how they fold, stay stable, and function in cellular membranes so future medicines can target membrane proteins more effectively.
-
Universal flu vaccine using self-assembling protein nanoparticles to present HA, NA, and M2e
Researchers are testing a new nanoparticle vaccine designed to trigger broad protection against many flu strains for people of all ages.
-
Optimizing HIV vaccine design to trigger cross-neutralizing antibodies
This grant tests a vaccine approach aimed at teaching the immune system to make antibodies that can neutralize diverse HIV strains across people.
-
HIV infection and engineered B cell memory in a humanized mouse model
Scientists are testing a new way to create HIV-fighting antibodies in a special mouse model to see if a functional cure could be possible without long-term antiretroviral therapy.
-
A druggable mito-nuclear feedback mechanism that preserves mitochondrial and synaptic function in old age
A new NIH-funded program aims to understand a brain mechanism that links mitochondria to gene control, with the goal of keeping brain cells happy in aging and Alzheimer's-related dementias.
-
Chemical tools to unlock new cancer drug targets
A research project to develop new chemical probes that can turn previously undruggable cancer-related proteins into drug targets to help patients.
-
Cell therapies to boost HIV bnAb responses in immune organoids
A research project aims to test a cell therapy that helps the body produce strong, long-lasting broad HIV antibodies using immune organoids derived from mouse, non-human primate, and human tissues.
-
Engineered B cells to fight HIV in non-human primates
Researchers are testing a way to reprogram a person’s own B cells so they can consistently produce anti-HIV antibodies in rhesus macaques, with the goal of moving toward a patient-friendly therapy.
-
IgH-reprogrammed B cells to produce HIV broadly neutralizing antibodies in mice
A mouse study will reprogram a patient's B cells to wear HIV-neutralizing antibodies on their surface, with the goal of generating durable immune protection.
-
Next-gen IgH reprogramming for in vivo delivery
A research project at Scripps aims to safely insert HIV-neutralizing antibody instructions into B cells inside the body to create lasting protective immune responses.
-
Immunogen Core: High-Quality Immunogens and Reagents for PlanB Projects
A core team will carefully choose and produce high-quality immunogens and reagents to support PlanB projects and help elicit durable antibody responses and memory B cells.
-
B cell engineering and clinical core for HIV bnAb durability
A center-led effort to engineer a patient’s own B cells to produce long-lasting HIV antibodies, aiming to help people with HIV maintain viral suppression without constant therapy.
-
Administrative Core for PlanB2CureHIV Consortium
A central Administrative Core will coordinate communication, planning, data sharing, and oversight for a multi-project HIV research consortium to keep work on track and within budget.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.